A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response

被引：0
作者：
Katrien De Wolf
Vibeke Kruse
Nora Sundahl
Mireille van Gele
Ines Chevolet
Reinhart Speeckaert
Lieve Brochez
Piet Ost
机构：
[1] University Hospital Ghent,Department of Radiation
[2] University Hospital Ghent,Oncology
[3] University Hospital Ghent,Department of Medical Oncology
来源：
Journal of Translational Medicine | / 15卷
关键词：
Cancer immunotherapy; Stereotactic body radiotherapy; Metastatic melanoma; Biomarkers; Immune monitoring;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 34 条
  • [21] Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma
    Jing Lin
    Qiaojuan Guo
    Zengqing Guo
    Tianzhu Lu
    Gang Chen
    Shaojun Lin
    Mei Chen
    Chuanben Chen
    Jianping Lu
    Jingfeng Zong
    Lina Tang
    Yu Chen
    Jianji Pan
    Radiation Oncology, 17
  • [22] Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma
    Lin, Jing
    Guo, Qiaojuan
    Guo, Zengqing
    Lu, Tianzhu
    Chen, Gang
    Lin, Shaojun
    Chen, Mei
    Chen, Chuanben
    Lu, Jianping
    Zong, Jingfeng
    Tang, Lina
    Chen, Yu
    Pan, Jianji
    RADIATION ONCOLOGY, 2022, 17 (01)
  • [23] The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma
    Coen, Oliver
    Corrie, Pippa
    Marshall, Helen
    Plummer, Ruth
    Ottensmeier, Christian
    Hook, Jane
    Bell, Sue
    Sagoo, Gurdeep S.
    Meads, David
    Bestall, Janine
    Velikova, Galina
    Gallagher, Ferdia A.
    Smith, Alexandra
    Howard, Helen
    Mason, Ellen
    Katona, Eszter
    Silva, Shobha
    Collinson, Michelle
    Rodwell, Simon
    Danson, Sarah
    BMC CANCER, 2021, 21 (01)
  • [24] The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma
    Oliver Coen
    Pippa Corrie
    Helen Marshall
    Ruth Plummer
    Christian Ottensmeier
    Jane Hook
    Sue Bell
    Gurdeep S. Sagoo
    David Meads
    Janine Bestall
    Galina Velikova
    Ferdia A. Gallagher
    Alexandra Smith
    Helen Howard
    Ellen Mason
    Eszter Katona
    Shobha Silva
    Michelle Collinson
    Simon Rodwell
    Sarah Danson
    BMC Cancer, 21
  • [25] KMT2C is a Potential Biomarker of Anti-PD-1 Treatment Response in Metastatic Melanoma
    Xie, Kuixia
    Peng, Yonglin
    Zhong, Wenying
    Liu, Xinhua
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2022, 27 (03):
  • [26] Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma
    da Silva, Ines Pires
    Ahmed, Tasnia
    McQuade, Jennifer L.
    Nebhan, Caroline A.
    Park, John J.
    Versluis, Judith M.
    Serra-Bellver, Patricio
    Khan, Yasir
    Slattery, Tim
    Oberoi, Honey K.
    Ugurel, Selma
    Haydu, Lauren E.
    Herbst, Rudolf
    Utikal, Jochen
    Pfoehler, Claudia
    Terheyden, Patrick
    Weichenthal, Michael
    Gutzmer, Ralf
    Mohr, Peter
    Rai, Rajat
    Smith, Jessica L.
    Scolyer, Richard A.
    Arance, Ana M.
    Pickering, Lisa
    Larkin, James
    Lorigan, Paul
    Blank, Christian U.
    Schadendorf, Dirk
    Davies, Michael A.
    Carlino, Matteo S.
    Johnson, Douglas B.
    Long, Georgina V.
    Lo, Serigne N.
    Menzies, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (10) : 1068 - +
  • [27] A Combined Proteomic and Transcriptomic Signature Is Predictive of Response to Anti-PD-1 Treatment: A Retrospective Study in Metastatic Melanoma Patients
    Mallardo, Domenico
    Fordellone, Mario
    White, Andrew
    Vowinckel, Jakob
    Bailey, Michael
    Sparano, Francesca
    Sorrentino, Antonio
    Mallardo, Mario
    Facchini, Bianca Arianna
    De Filippi, Rosaria
    Ferrara, Gerardo
    Vanella, Vito
    Beeler, Kristina
    Chiodini, Paolo
    Cesano, Alessandra
    Warren, Sarah
    Ascierto, Paolo A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (17)
  • [28] Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
    Sachpekidis, Christos
    Kopp-Schneider, Annette
    Pan, Leyun
    Papamichail, Dimitrios
    Haberkorn, Uwe
    Hassel, Jessica C.
    Dimitrakopoulou-Strauss, Antonia
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (06) : 1932 - 1943
  • [29] Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients
    Leila Khoja
    Minnie Kibiro
    Ur Metser
    Craig Gedye
    David Hogg
    Marcus O Butler
    Eshetu G Atenafu
    Anthony M Joshua
    British Journal of Cancer, 2016, 115 : 1186 - 1192
  • [30] Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
    Christos Sachpekidis
    Annette Kopp-Schneider
    Leyun Pan
    Dimitrios Papamichail
    Uwe Haberkorn
    Jessica C. Hassel
    Antonia Dimitrakopoulou-Strauss
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 1932 - 1943
1234